A £5.2 million ($8 million) milestone has been reached by Concert Pharmaceuticals and Celgene Corporation for the completion of a phase one clinical evaluation of CTP-730
Concert Pharmaceuticals and Celgene Corporation's phase one trials of CTP-730 reaches £ 5.2 million
CTP-730 is a deuterium-modified analogue of apremilast, a selective phosphodiesterase 4 (PDE4) inhibitor.
Once-daily dosing of 50 mg of CTP-730 administered for seven days in the phase one trial demonstrated similar steady-state exposure to historical data for 30 mg of apremilast administered twice daily.
Roger Tung, president and chief executive officer of Concert Pharmaceuticals, said: “We are encouraged by the favourable pharmacokinetic profile of CTP-730 observed in our phase one clinical trials.
“We believe that selective incorporation of deuterium in apremilast has resulted in a potential next generation anti-inflammatory agent.”